Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-71...
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
About this item
Full title
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Publisher
Melbourne: News Bites Pty Ltd
Journal title
News Bites US - NASDAQ, 2024
Language
English
Formats
Publication information
Publisher
Melbourne: News Bites Pty Ltd
Subjects
More information
Alternative Titles
Full title
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_3117203852
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_3117203852
How to access this item
Log in as a Library member
